Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Stock analysts at Oppenheimer Holdings dropped their FY2017 earnings per share (EPS) estimates for Intellia Therapeutics in a note issued to investors on Tuesday. Oppenheimer Holdings analyst L. Cann now forecasts that the company will post earnings of ($1.71) per share for the year, down from their prior forecast of ($1.66). Oppenheimer Holdings has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Intellia Therapeutics’ Q4 2017 earnings at ($0.46) EPS, Q1 2018 earnings at ($0.52) EPS, Q2 2018 earnings at ($0.58) EPS, Q3 2018 earnings at ($0.51) EPS, Q4 2018 earnings at ($0.55) EPS, FY2018 earnings at ($2.16) EPS, FY2019 earnings at ($3.47) EPS, FY2020 earnings at ($4.74) EPS and FY2021 earnings at ($3.72) EPS.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Tuesday, October 31st. The company reported ($0.44) earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.06. Intellia Therapeutics had a negative return on equity of 27.19% and a negative net margin of 215.92%. The company had revenue of $7.30 million during the quarter, compared to analyst estimates of $5.83 million. During the same quarter last year, the firm posted ($0.22) EPS. The firm’s revenue for the quarter was up 49.0% on a year-over-year basis.

WARNING: “Intellia Therapeutics, Inc. to Post FY2017 Earnings of ($1.71) Per Share, Oppenheimer Holdings Forecasts (NTLA)” was published by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/11/02/intellia-therapeutics-inc-to-post-fy2017-earnings-of-1-71-per-share-oppenheimer-holdings-forecasts-ntla.html.

NTLA has been the topic of a number of other reports. Chardan Capital downgraded Intellia Therapeutics from a “buy” rating to a “neutral” rating and set a $20.00 price target on the stock. in a report on Tuesday, August 29th. Jefferies Group LLC set a $42.00 price objective on Intellia Therapeutics and gave the company a “buy” rating in a research report on Tuesday. ValuEngine upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, September 22nd. Wedbush reiterated an “ourperform” rating and set a $25.00 price objective (down previously from $29.00) on shares of Intellia Therapeutics in a research report on Wednesday, September 27th. Finally, Leerink Swann upped their price objective on Intellia Therapeutics from $29.00 to $37.00 and gave the company an “outperform” rating in a research report on Tuesday. They noted that the move was a valuation call. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $29.50.

Institutional investors and hedge funds have recently modified their holdings of the business. Neuberger Berman Group LLC increased its position in Intellia Therapeutics by 14.9% in the second quarter. Neuberger Berman Group LLC now owns 49,517 shares of the company’s stock worth $792,000 after buying an additional 6,431 shares in the last quarter. American Century Companies Inc. purchased a new stake in Intellia Therapeutics in the second quarter worth about $583,000. Bank of Montreal Can increased its position in Intellia Therapeutics by 1,031.7% in the second quarter. Bank of Montreal Can now owns 7,922 shares of the company’s stock worth $127,000 after buying an additional 7,222 shares in the last quarter. OxFORD Asset Management LLP purchased a new stake in Intellia Therapeutics in the second quarter worth about $1,132,000. Finally, Rhumbline Advisers purchased a new stake in Intellia Therapeutics in the second quarter worth about $275,000. Institutional investors and hedge funds own 47.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene.

Earnings History and Estimates for Intellia Therapeutics (NASDAQ:NTLA)

Receive News & Ratings for Intellia Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellia Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.